Title of article
Editorial Comment: Cardiotoxicity due to chemotherapy for breast cancer: The dark side of the moon
Author/Authors
Peruzzi, Mariangela Sapienza University of Rome - Department of Medico-Surgical Sciences and Biotechnologies, Italy , Palazzoni, Giovanni Sapienza University of Rome - Department of Medico-Surgical Sciences and Biotechnologies, Italy , Biondi-Zoccai, Giuseppe Sapienza University of Rome - Department of Medico-Surgical Sciences and Biotechnologies, Italy , Lotrionte, Marzia University of the Sacred Heart - Division of Heart Failure and Cardiac Rehabilitation Unit Catholic, Italy
From page
61
To page
62
Abstract
Despite major advancements in breast cancer therapy, there is a growing awareness of the potentially negative cardiac effects of cancer treatment (1, 2). Indeed, the prevention and management of heart disease in patients with cancer present special challenges to the cardiologist, and even new oncologic treatments may bear the potential for cardiotoxicity. In addition, prolonged survival, as a result of improved cancer therapy, allows persons to live long enough that cardiac toxicity can be the main determinant of quality of life and life expectancy (3). In such a scenario, it is crucial to set up long-standing cooperation between oncologists and cardiologists for the optimal management of patients with cancer (4).
Journal title
The Anatolian Journal of Cardiology: Andolu Kardiyoloji Dergisi
Journal title
The Anatolian Journal of Cardiology: Andolu Kardiyoloji Dergisi
Record number
2693127
Link To Document